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Abstract
Background: World maps are among the most effective ways to convey public health messages such as
recommended vaccinations, but creating a useful and valid map requires careful deliberation. The changing
epidemiology of hepatitis A virus (HAV) in many world regions heightens the need for up-to-date risk maps. HAV
infection is usually asymptomatic in children, so low-income areas with high incidence rates usually have a low
burden of disease. In higher-income areas, many adults remain susceptible to the virus and, if infected, often
experience severe disease.
Results: Several challenges associated with presenting hepatitis A risk using maps were identified, including the
need to decide whether prior infection or continued susceptibility more aptly indicates risk, whether to display
incidence or prevalence, how to distinguish between different levels of risk, how to display changes in risk over
time, how to present complex information to target audiences, and how to handle missing or obsolete data.
Conclusion: For future maps to be comparable across place and time, we propose the use of the age at midpoint
of population susceptibility as a standard indicator for the level of hepatitis A endemicity within a world region.
We also call for the creation of an accessible active database for population-based age-specific HAV seroprevalence
and incidence studies. Health risk maps for other conditions with rapidly changing epidemiology would benefit
from similar strategies.
Keywords: hepatitis A, geographic information systems, health risk maps, risk mapping, vaccine recommendations,
global health, travel health
Background
Maps are valuable tools for epidemiologic research and
application, and are particularly effective in communi-
cating key public health messages to a wide range of
audiences. One example of the importance of global risk
maps relates to the display of vaccination recommenda-
tions for hepatitis A virus (HAV), an infectious disease
strongly linked to income, access to clean water, and
access to sanitation [1]. Most children in low-income
areas become infected in early childhood when HAV
infections are typically asymptomatic, and infection con-
fers lifelong immunity. Thus, in low-income areas the
incidence of infection is usually high, but the disease
burden is low and hepatitis A is not considered to be a
major public health problem. In contrast, hepatitis A is
a growing public health concern in high-income areas
where the infection rate is usually low, since many
adults remain susceptible to HAV and are at risk of
severe symptoms and death [2-4]. Additionally, hepatitis
A may cause a significant economic burden to indivi-
duals, families, and communities, especially in areas
with a sizeable proportion of susceptible older adults
[5-7]. This is the paradox of hepatitis A risk, and one of
the reasons why mapping this risk is such a challenge:
residents of areas with a high infection transmission rate
have a lower rate of severe disease and death than those
living in areas with intermediate or low infection rates.
The most recent global estimates of anti-HAV IgG
seroprevalence suggest that an epidemiological transition
is occurring in many countries and regions, with the
incidence of infection in most of the world declining
[8,9]. As a result, the proportion of susceptible adults in
these countries is increasing. Contaminated food and
water are responsible for a considerable proportion of
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incident HAV cases, and the globalization of the food
system, which increases the likelihood of food from
endemic areas being shipped to and consumed in low-
endemicity areas, may place susceptible adults and chil-
dren in low anti-HAV prevalence areas at risk [10-12].
Travel from low-endemicity areas to places where hepa-
titis A is endemic is also often reported as a source of
infection [13-17]. Just as with infection acquired from
imported foods, returning travelers may bring the infec-
tion to their hometowns and spark community out-
breaks [2,6,13,15,17-19].
Because of these changes in HAV risk and, conse-
quently, the shifting epidemiologic profiles of HAV in
diverse parts of the world, there is a pressing need for
up-to-date information and risk maps for both residents
of areas in transition and travelers to these areas. This
information is required by public health authorities
making immunization policies, health care practitioners
making recommendations about vaccination, and indivi-
duals making health decisions for themselves and their
families. Maps are one of the most effective ways to
rapidly convey information about global issues [20].
However, maps can only display a limited amount of
information, and complex decisions must be made
about what information to display and how best to dis-
play it. This paper examines and compares the features
of several commonly used hepatitis A risk maps, charac-
terizes the key challenges of displaying hepatitis A risk
on a map based on observations of these widely-used
maps, and outlines potential approaches to improving
maps for use by policymakers and health practitioners.
Results
Based on our comparison of five commonly-referenced
hepatitis A risk maps (Table 1), we identified five key
challenges associated with presenting hepatitis A risk:
Table 1 Comparison of commonly accessed hepatitis A maps
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1. Defining high risk
Most maps can only display one aspect of risk, and this
is a challenge for hepatitis A since there are multiple
ways to define and present risk. All of the five maps we
examined used some indicator of the seroprevalence
rate (the proportion of a population with immunity to
hepatitis A based on past infection), often reported as
the more generic “endemicity” rather than as specific
percentages, as their measure of risk. A high seropreva-
lence rate, especially a high rate among children, is evi-
dence of a high incidence rate (the rate of new
infection) in the population. Individuals living in areas
with high incidence rates usually acquire the infection
in early childhood, when the risk of severe disease is
minimal. Maps that illustrate anti-HAV immunity rates
across the globe are useful for persons traveling from
areas with low incidence rates to areas with high trans-
mission rates since these individuals may have a signifi-
cant risk of becoming infected during travel if they have
not had prior infection or immunization (Figure 1).
However, the opposite scale–one designating areas
with a high proportion of susceptible adults as the
“high risk” category on the map rather than showing
immunity as the evidence of high risk–might better
convey the risk of severe disease. A map showing adult
susceptibility (Figure 2) might more effectively indicate
where the case fatality rate is likely to be highest
should an outbreak occur, since the risk of severe mor-
bidity and mortality increases with increasing age. This
message about risk might be the most appropriate one
for policymakers from regions with moderate or high
susceptibility rates, since these may be the areas where
hepatitis A has the greatest likelihood of becoming a
major public health problem. Additionally, such a map
would warn travelers from “high risk of susceptibility”
areas that they are likely to be at risk of hepatitis A
disease and should be vaccinated before international
travel to regions of the world with different hepatitis A
profiles.
One limitation of using seroprevalence data rather
than incidence data is that the majority of adults in a
population with immunity to HAV probably acquired
the infection decades ago when they were young chil-
dren, so prevalence data may capture past conditions
much more than current risks. Thus, a risk map might
best display incidence rates rather than seroprevalence
rates. However, HAV infection incidence is often very
difficult to measure. Case detection and reporting are
very low since many cases of HAV infection are asymp-
tomatic or have only mild symptoms, especially among
children. Furthermore, the capacity for conducting hepa-
titis A surveillance varies by country.
Figure 1 Global risk map of HAV immunity in 2005.
Mohd Hanafiah et al. International Journal of Health Geographics 2011, 10:57
http://www.ij-healthgeographics.com/content/10/1/57
Page 3 of 8
2. Defining levels of risk
Defining the values that separate categories of risk is
another important consideration for mapmakers. Since
there are no well-established definitions for which inci-
dence or prevalence rates constitute high or low hepati-
tis A risk, most of the five hepatitis A maps we
examined present vague categories such as “endemicity
level” rather than providing a key showing the quantita-
tive criteria used to assign each entity on the map to
one of the risk categories. One outcome of the different,
and usually undisclosed, scales used by different map-
makers is that the resulting maps lack comparability.
However, attempting to be more precise about the rates
displayed might be inappropriate for two reasons.
The first concern is that many countries lack current
data about hepatitis A incidence and anti-HAV seropre-
valence rates. In the absence of good data, mapmakers
must make “best guesses” about the likely transmission
rate in an area. This requires making judgment calls
about whether to assume that the risk profile has not
changed (likely remaining “high”) or to assume that over
time the risk profile has changed (maybe becoming
“moderate”), perhaps based on a comparison of rela-
tively nearby places with more current data. Assigning
these estimates to categories listing actual incidence or
prevalence rates may imply a greater level of certainty
about the classification than is appropriate. Maps cre-
ated without good primary data may be interpreted to
be authoritative by policymakers and others who are
involved in making important decisions about vaccina-
tion recommendations, public health initiatives, and
other potentially costly interventions, even if the map-
makers are candid about data limitations.
The second concern is that even if current data were
available from all countries, it might be misleading to
assign two regions with very similar seroprevalence rates
to different risk categories simply because those rates
happen to fall on opposite sides of a cutoff point. When
appropriate, the cutoff points should be adjusted to
avoid fine distinctions that do not represent differences
that are meaningful.
3. Capturing changes over time
Another issue related to the definition of risk categories
is whether risk should be defined in relative terms or if
cutoffs for higher and lower risk levels should be based
on a consistent scale. Significant shifts in hepatitis A
risk and susceptibility are occurring in most world
regions [8,9], and it is important for risk maps to reflect
those changes. For example, Figures 1 and 3 use the
same risk definition and cutoffs for anti-HAV seropreva-
lence to illustrate that some regions transitioned from a
Figure 2 Global risk map of HAV susceptibility in 2005.
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high risk category in 1990 (Figure 3) to a lower risk
category in 2005 (Figure 1).
If absolute rates are used to assign risk levels, several
world regions would move into a lower risk category
between 1990 and 2005. If relative rather than absolute
measures are used, a world region classified as high risk
for hepatitis A in 1990 that experienced a significant
decrease in incidence over the subsequent 15 years
might still be classified as high risk in 2005 if other
regions experienced similar declines in incidence,
because that region would continue to have high risk
relative to other regions. Maps that obscure meaningful
shifts in disease risk over time may hinder the re-evalua-
tion of vaccination policies and other important public
health considerations.
4. Anticipating user needs
Maps are usually created to meet the needs of one or
more specific “consumers” of health information. Several
of the maps selected for comparison were made for tra-
velers (or, more specifically, for travelers from areas
with low anti-HAV seroprevalence rates and a corre-
spondingly high proportion of susceptible adults). The
risk presented by travel health risk maps is intended to
translate into vaccination recommendations for trave-
lers. Maps created to guide immunization policy for
local residents would look quite different from those
designed to display vaccine recommendations for trave-
lers (Table 2).
The process of creating maps that meet the needs of
various consumers can involve sensitive decisions about
how to portray risk to the target populations. Health
and tourism officials in countries with intermediate
hepatitis A incidence rates and those from countries
with low transmission in cities but high transmission in
rural areas may prefer to have their countries presented
as low risk areas in order to avoid a negative impact on
trade and tourism. Alternatively, health officials may
prefer to have their countries displayed as high risk to
encourage all potentially susceptible travelers to seek
vaccination prior to travel, reducing the risk of travel-
related hepatitis A infection and potential secondary
spread when the traveler returns home. Similarly, some
travel medicine specialists prefer country-level maps
that simply state the need for vaccination as present or
absent for travelers, while other physicians want to
know the risk at a finer spatial scale so they can make
more nuanced recommendations to their clients based
on their particular travel itineraries.
Additionally, while policymakers are usually looking
for hepatitis A maps that display the disease risk for
resident populations–information that will be used to
Figure 3 Global risk map of HAV immunity in 1990.
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decide whether universal vaccination, targeted vaccina-
tion, or no vaccination appears to be the most appropri-
ate for the population as a whole–travelers and travel
medicine specialists want to know the risk to individual
travelers. No map will ever be fully suitable for an indi-
vidual traveler, since a traveler’s personal vulnerability
depends not only on the country of origin and the desti-
nation country but also on a host of other factors, such
as personal medical history, the duration of the stay,
and the activities in which the traveler intends to engage
[14]. Even so, health risk maps intended to display risk
to populations are often used to make individual health
decisions, and mapmakers must reflect on how their
maps may be interpreted–and perhaps misinterpreted–
and consider how they can most clearly convey the
intended use of the map.
5. Handling missing or obsolete data
The data sources for most of the maps we examined
were not immediately clear, but many countries and
regions are known to have incomplete or obsolete data
[9]. Furthermore, most world regions have some coun-
tries that dominate the available data and some coun-
tries for which no recent data are available.
One common way to handle missing data is to map at
the regional level rather than using smaller mapping
units such as countries. However, this may hide differ-
ences known to exist within some regions where ample
data are available, and may limit the usefulness of the
map [21]. The differences known to exist within some
regions may have important policy and practice implica-
tions. For example, a susceptible traveler heading to a
rural part of an intermediate-risk country may be at sig-
nificantly increased risk of acquiring hepatitis A com-
pared to a similar traveler who intends to stay in cities.
A world map displaying risk that is only accurate to the
country level will not provide enough information about
heterogeneity within mapped areas to distinguish
between the risk profiles of travelers to rural and urban
locations.
Another approach is to leave blank those countries
or areas lacking current HAV epidemiologic informa-
tion. However, leaving blank spaces has been shown to
interfere with pattern recognition [22], and since most
countries without recent data are presumed to have
high incidence rates it might be irresponsible not to
mark those areas as having high risk for travelers. A
third option is to provide an indicator that shows the
level of evidentiary support available for each mapping
unit, but this may be far too much information to dis-
play on a map intended for use by a wide range of
consumers.
Table 2 Summary of risk of hepatitis A to travelers and typical vaccine recommendations by Global Burden of Disease
(GBD) Study region
Region Risk to travelers from low-risk areas [9] Typical Vaccine Recommendation
for travelers to region [23,24] for residents of region [6]
South sub-Saharan Africa Very High Recommended Not recommended
West sub-Saharan Africa Very High Recommended Not recommended
South Asia Very High Recommended Not recommended
Central sub-Saharan Africa Very High Recommended Not recommended
East sub-Saharan Africa Very High Recommended Not recommended
Central Latin America High Recommended Targeted
Andean Latin America High Recommended Targeted
Central Asia High Recommended Targeted
Southern Latin America High Recommended Targeted
Tropical Latin America High Recommended Targeted
North Africa/Middle East High Recommended Targeted
Oceania High Recommended Targeted
Caribbean Intermediate Recommended Universal
Southeast Asia Intermediate Recommended Universal
Eastern Europe Intermediate Recommended Universal
East Asia Intermediate Recommended Universal
High-income Asia Pacific Low Not recommended Targeted
Australasia Low Not recommended Targeted
Western Europe Low Not recommended Targeted
High-income North America Low Not recommended Targeted
Mohd Hanafiah et al. International Journal of Health Geographics 2011, 10:57
http://www.ij-healthgeographics.com/content/10/1/57
Page 6 of 8
Discussion
We identified several inadequacies of current global risk
maps for hepatitis A: the definition of risk using vague
terms like endemicity rather than incidence or preva-
lence; the use of inconsistent thresholds for risk cate-
gories, which makes it difficult to compare maps and
identify trends over time; failure to acknowledge data
sources and to identify when data are unavailable or
obsolete; and failure to clearly identify appropriate uses
of particular maps. These limitations demonstrate the
need for improvement in hepatitis A mapmaking
practices.
In order for maps to be comparable across place and
time, mapmakers need to provide information about the
measures of risk they are displaying and the cutoffs they
used to distinguish between various risk categories. The
inability to accurately measure incidence and uncer-
tainty about how to interpret age-seroprevalence data
for HAV have led most mapmakers to instead display a
vague “endemicity level” rather than a more concrete
measure of risk. One option we support for making
“endemicity” a more measurable concept is to adopt the
use of “age at midpoint of population susceptibility” as
an indicator of endemicity (as illustrated in Figures 1
and 3). The age at midpoint of population susceptibility
may be more helpful as an indicator for trends over
time than the prevalence at a particular age, even
though it would change more slowly than measures that
are more immediately affected by incidence rates. Alter-
natively, the proportion of a population with anti-HAV
at age 10 or age 30 or some other age could be an
option for defining the endemicity level.
The greatest limitation to making up-to-date global
hepatitis A risk maps is the absence of current represen-
tative data from many parts of the world. The creation
of an active global database of HAV seroprevalence and
incidence data by age and jurisdiction would be valuable
for risk assessment and for ensuring that new maps are
accurate and current. A model for this type of database
exists: the European Region of the World Health Orga-
nization’s Centralized Information System for Infectious
Diseases (CISID). This online database provides infec-
tious disease surveillance data for the Member States in
the European region. For hepatitis A, CISID presently
includes reported annual cases and annual case rates
(expressed as cases per 100,000 population) by country.
This database is very powerful, but it lacks the age-spe-
cific hepatitis A information that is critical for monitor-
ing changing HAV epidemiology over time.
Furthermore, all reporting entities may not be using
uniform case definitions that include laboratory confir-
mation, and that may limit the comparability and relia-
bility of the statistics in this database. Even with these
shortcomings in the CISID database, the creation of
similar systems in other world regions would be highly
beneficial to public health. Collecting both historical and
current data from the smallest subnational geographic
units possible would allow for epidemiological changes
to be quickly detected and for policies to be updated in
a timely manner. Such a database would also allow for
the development of better predictive models based on
socioeconomic indicators that are known to be strongly
correlated with hepatitis A incidence [1]. Ideally, mem-
bers of the hepatitis A research and practice community
can work together to create and maintain an improved
data sharing and data management system. In the mean-
while, mapmakers should be sure to provide information
about their data sources and the limitations of the cur-
rently available data and estimates, in addition to follow-
ing other good mapmaking practices such as making
sure that each map has a clear title and a legend that
identifies the nature of the data presented and the
sources of the data (including their years of collection
and references to the documents from which the data
were compiled).
Conclusions
Improved water and sanitation systems in many parts of
the world have saved millions of children from severe
diarrheal disease, and allowed those individuals to reach
adulthood without having been exposed to the hepatitis
A virus and developed immunity to it. This is the para-
doxical nature of hepatitis A risk: the lower infection
rate associated with development may be responsible for
increasing morbidity and mortality from the disease.
The growing population of susceptible adults worldwide
makes the availability of current, accurate, and valid risk
maps important for public health and individual well-
being. The tools we propose here would help policy-
makers, health practitioners, and researchers to better
understand and address the changing epidemiology of
HAV infection and the emerging threat from hepatitis A
disease.
Similar challenges are associated with the creation of
maps for other complex and emerging infections, espe-
cially vaccine-preventable infections for which maps are
used to disseminate vaccination recommendations. The
solutions we propose for these hepatitis A maps would
apply equally well to those other conditions.
Methods
Literature review
Five hepatitis A maps were selected for comparison
based on a review of the maps presented in published
articles indexed in PubMed, a review of the websites of
major health organizations such as the World Health
Organization (WHO) and the U.S. Centers for Disease
Control and Prevention (CDC), image searches using
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major Internet search engines, and consultation with
experts of travel medicine and hepatitis A epidemiology.
Two of the five maps selected were produced by health
agencies, one from the WHO’s International Travel and
Health book (2008) [23] and one from the CDC’s Yellow
Book (2008) [24] that focuses on travel health. The
remaining three maps were from peer-reviewed journal
articles [9,25,26]. The titles, data sources, target audi-
ence, definitions of risk, risk levels, and notes included
with each map were examined.
Mapping hepatitis A risk
Global hepatitis A risk maps for 1990 and 2005 were
produced in consultation with the World Health Orga-
nization’s Public Health Mapping and Geographic Infor-
mation Systems (GIS) program. Age-specific
seroprevalence estimates for 1990 and 2005 for each of
the 21 Global Burden of Disease (GBD) world regions
were derived from curves fit to pooled data collected
between 1985 and 1994 and between 1995 and 2008,
respectively, as reported elsewhere [9]. Risk is indicated
by the age at midpoint of population immunity to HAV,
which is defined as the age at which at least half of the
population in that age group has anti-HAV IgG antibo-
dies indicating past exposure to the virus. Each of the
GBD world regions was categorized as a low, intermedi-
ate, high, or very high risk area based on its age at mid-
point of population immunity (for Figures 1 and 3) or
susceptibility (for Figure 2).
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